CStone Pharma of Suzhou raised $260 million in a Series B financing, which the company claims is the largest Series B round for any China biopharma. A two-year-old company, CStone has now raised $410 million to support its ambitious portfolio of ten immuno-oncology candidates. The company is focused on discovering new combinations of drugs that address cancers with high incidence in China. The B round was led by GIC Private Limited, Singapore’s sovereign wealth fund, and joined by a list of well-known new and existing investors.
Source: China Biotoday
